Alejandro Rico Mendoza
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alejandro Rico Mendoza has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
- Alexandra Porras-Ramírez
Grupo de Medicina Comunitaria y Salud Colectiva, Universidad El Bosque, Bogotá, Colombia
12 shared publications - Aileen Y. Chang
Department of Medicine, George Washington University, Washington, DC, USA
3 shared publications - Jorge Andrés Urquijo Méndez
Grupo de Medicina Comunitaria y Salud Colectiva, Universidad El Bosque, Bogotá, Colombia
3 shared publications - Juan Fernando Ramon
Department of Neurosurgery, Fundacion Santa Fe de Bogota, Bogota, Colombia
3 shared publications Liliana Encinales
Department of Medicine, Allied Research Society LLC, Barranquilla, 080020, Atlántico, Colombia
3 shared publications- Liliana Encinales
Allied Research Society Colombia SAS, Barranquilla, Colombia
3 shared publications
Latest Publications
- Open Access
Factors associated with congenital syphilis among women with gestational syphilis in a public health network in Bogotá, Colombia, 2017–2024: A case-control study
Background: Congenital syphilis remains a preventable cause of perinatal morbidity and mortality, and its incidence in Colombia remains well above the elimination target. We aimed to identify maternal and prenatal care factors associated with congenital syphilis among women with gestational syphilis attended in a public health network serving socially vulnerable populations in Bogotá, Colombia. Methods: We conducted a retrospective case-control study using surveillance and clinical records from the Subred Integrada de Servicios de Salud Sur E.S.E. for pregnancies ending between 2017 and 2024. Cases were neonates with congenital syphilis according to national surveillance criteria; controls were neonates without congenital syphilis born to mothers with gestational syphilis in the same network. Factors associated with congenital syphilis were identified using multivariable logistic regression with backward elimination. Results: We included 743 mother–infant pairs (285 cases and 458 controls). Maternal diagnosis after 28 weeks of gestation (adjusted odds ratio 17.75; 95% confidence interval 11.81–26.69), absence of prenatal care compared with eight or more visits (12.74; 5.03–32.25) and reinfection during pregnancy (3.02; 1.73–5.29) were independently associated with congenital syphilis, whereas a documented history of syphilis was associated with lower odds (0.45; 0.25–0.82). The model showed high discrimination (area under the receiver operating characteristic curve 0.860). Migrant status was associated with congenital syphilis in the crude analysis but not after adjustment. Conclusions: Congenital syphilis in this setting was associated mainly with late maternal diagnosis and absent prenatal care, conditions that preclude timely benzathine penicillin treatment. Strengthening early prenatal screening, continuity of care and partner management may reduce vertical transmission in socially vulnerable urban populations.
Open AccessFactors associated with congenital syphilis among women with gestational syphilis in a public health network in Bogotá, Colombia, 2017–2024: A case-control study
Background: Congenital syphilis remains a preventable cause of perinatal morbidity and mortality, and its incidence in Colombia remains well above the elimination target. We aimed to identify maternal and prenatal care factors associated with congenital syphilis among women with gestational syphilis attended in a public health network serving socially vulnerable populations in Bogotá, Colombia. Methods: We conducted a retrospective case-control study using surveillance and clinical records from the Subred Integrada de Servicios de Salud Sur E.S.E. for pregnancies ending between 2017 and 2024. Cases were neonates with congenital syphilis according to national surveillance criteria; controls were neonates without congenital syphilis born to mothers with gestational syphilis in the same network. Factors associated with congenital syphilis were identified using multivariable logistic regression with backward elimination. Results: We included 743 mother–infant pairs (285 cases and 458 controls). Maternal diagnosis after 28 weeks of gestation (adjusted odds ratio 17.75; 95% confidence interval 11.81–26.69), absence of prenatal care compared with eight or more visits (12.74; 5.03–32.25) and reinfection during pregnancy (3.02; 1.73–5.29) were independently associated with congenital syphilis, whereas a documented history of syphilis was associated with lower odds (0.45; 0.25–0.82). The model showed high discrimination (area under the receiver operating characteristic curve 0.860). Migrant status was associated with congenital syphilis in the crude analysis but not after adjustment. Conclusions: Congenital syphilis in this setting was associated mainly with late maternal diagnosis and absent prenatal care, conditions that preclude timely benzathine penicillin treatment. Strengthening early prenatal screening, continuity of care and partner management may reduce vertical transmission in socially vulnerable urban populations.
- 2 September 2026
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 31 (10) , 2169-2178
Cost-utility analysis of CAR-T therapy compared to standard of care in patients with relapsed/refractory diffuse large B-cell lymphoma in Colombia, 2025
- 2 September 2026
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 31 (10) , 2169-2178
Cost-utility analysis of CAR-T therapy compared to standard of care in patients with relapsed/refractory diffuse large B-cell lymphoma in Colombia, 2025
- Open Access
- 14 August 2026
- Published by MDPI AG in Journal of Fungi
- Vol. 12 (8) , 608
Clinical and Economic Trade-Offs in Antifungal Therapy for Invasive Aspergillosis and Mucormycosis: A Markov Model–Based Analysis
Invasive aspergillosis and mucormycosis are life-threatening fungal infections characterized by high early mortality, substantial toxicity, and intensive healthcare resource utilization. While multiple antifungal therapies are recommended in international guidelines, their comparative clinical and economic value remains uncertain, particularly in resource-limited settings. We developed a hybrid decision tree and Markov model to evaluate antifungal strategies, including liposomal amphotericin B, isavuconazole, voriconazole, posaconazole, and caspofungin, from the perspective of the Colombian healthcare system over a 6-month horizon. Health states included clinical response, treatment failure, toxicity, and death. Outcomes included quality-adjusted life-years (QALYs), costs, incremental cost-effectiveness ratios (ICERs), and net monetary benefit (NMB). Deterministic and probabilistic sensitivity analyses were performed. In invasive aspergillosis, isavuconazole provided a modest incremental benefit over voriconazole (+0.022 QALYs), driven primarily by improved tolerability, at an incremental cost of COP 3.4 million, yielding an ICER of COP 154.5 million/QALY. In mucormycosis, liposomal amphotericin B yielded greater survival benefits (+0.035 QALYs) but at substantially higher costs (ICER: COP 494.3 million/QALY). Across willingness-to-pay thresholds, isavuconazole and voriconazole demonstrated more favorable economic profiles, owing to lower toxicity and reduced hospitalizations. These findings highlight that the clinical–economic value of antifungal therapy is primarily determined by early survival gains, toxicity burden, and front-loaded costs. Strategies minimizing toxicity and hospitalization appear more efficient in constrained health systems, whereas survival-maximizing approaches may be justified in severe disease. This integrated analysis supports context-specific antifungal decision-making in the management of invasive fungal infections.
- 14 August 2026
- Published by MDPI AG in Journal of Fungi
- Vol. 12 (8) , 608
Open AccessClinical and Economic Trade-Offs in Antifungal Therapy for Invasive Aspergillosis and Mucormycosis: A Markov Model–Based Analysis
Invasive aspergillosis and mucormycosis are life-threatening fungal infections characterized by high early mortality, substantial toxicity, and intensive healthcare resource utilization. While multiple antifungal therapies are recommended in international guidelines, their comparative clinical and economic value remains uncertain, particularly in resource-limited settings. We developed a hybrid decision tree and Markov model to evaluate antifungal strategies, including liposomal amphotericin B, isavuconazole, voriconazole, posaconazole, and caspofungin, from the perspective of the Colombian healthcare system over a 6-month horizon. Health states included clinical response, treatment failure, toxicity, and death. Outcomes included quality-adjusted life-years (QALYs), costs, incremental cost-effectiveness ratios (ICERs), and net monetary benefit (NMB). Deterministic and probabilistic sensitivity analyses were performed. In invasive aspergillosis, isavuconazole provided a modest incremental benefit over voriconazole (+0.022 QALYs), driven primarily by improved tolerability, at an incremental cost of COP 3.4 million, yielding an ICER of COP 154.5 million/QALY. In mucormycosis, liposomal amphotericin B yielded greater survival benefits (+0.035 QALYs) but at substantially higher costs (ICER: COP 494.3 million/QALY). Across willingness-to-pay thresholds, isavuconazole and voriconazole demonstrated more favorable economic profiles, owing to lower toxicity and reduced hospitalizations. These findings highlight that the clinical–economic value of antifungal therapy is primarily determined by early survival gains, toxicity burden, and front-loaded costs. Strategies minimizing toxicity and hospitalization appear more efficient in constrained health systems, whereas survival-maximizing approaches may be justified in severe disease. This integrated analysis supports context-specific antifungal decision-making in the management of invasive fungal infections.
- Open Access
- 2 March 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Toxicities associated with CAR-T therapy compared with standard treatments in hematologic malignancies: a systematic review and meta-analysis
Chimeric antigen receptor T-cell (CAR-T) treatment has revolutionized the therapeutic approach for relapsed or refractory hematologic malignancies. But its
- 2 March 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Open AccessToxicities associated with CAR-T therapy compared with standard treatments in hematologic malignancies: a systematic review and meta-analysis
Chimeric antigen receptor T-cell (CAR-T) treatment has revolutionized the therapeutic approach for relapsed or refractory hematologic malignancies. But its
- Open Access
- 6 September 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 229, 115768
Performance evaluation of machine learning models in cervical cancer diagnosis: Systematic review and meta-analysis
- 6 September 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 229, 115768
Open AccessPerformance evaluation of machine learning models in cervical cancer diagnosis: Systematic review and meta-analysis
- Open Access
- 31 January 2024
- Published by Wiley
Systematic literature review 2007-2021 Impact of reduced-intensity or nonmyeloablative conditioning regimen in pediatric ALL patients undergoing allogeneic hematopoietic stem cell transplantation
Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment option for patients with acute lymphoblastic leukemia (ALL) very high-risk in first complete remission and relapsed disease that achieve remission patients. There is considerable variability in the regimens preparatory for conditioning patients to be transplanted. In this systematic review, we identify the impact of reduced-intensity regimen (RIC) or non-myeloablative (NMAC) on HSCT in pediatric ALL patients in terms of overall survival (OS) and disease-free survival (DFS) as reported in the scientific literature. Information was searched on nine databases, gray literature and bibliography cited in the selected articles, describing the results of HSCT in ALL in children between January 01, 2007, and June 30, 2021, with different preparative regimens. The literature search yielded an overall of 3841 articles; two articles were duplicates and rejected. This first selection included 363 articles, and 95 were selected for a complete reading. Finally, 16 articles that met the inclusion and exclusion criteria were included, which analyzed 2136 patients with ALL. RIC, NMAC, or reduced-intensity myeloablative regimen (RTMAC) was administered to 520 patients, demonstrating OS and DFS like other cohorts undergoing MAC. This article concludes the use of RIC, NMAC, or RTMAC is a reasonable option for those patients with ALL who require a transplant and who suffer from other comorbidities or have previous transplants, offering survival rates comparable with myeloablative regimens that, in combination with new alternatives such as immunotherapy, may become the best alternative.
- 31 January 2024
- Published by Wiley
Open AccessSystematic literature review 2007-2021 Impact of reduced-intensity or nonmyeloablative conditioning regimen in pediatric ALL patients undergoing allogeneic hematopoietic stem cell transplantation
Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment option for patients with acute lymphoblastic leukemia (ALL) very high-risk in first complete remission and relapsed disease that achieve remission patients. There is considerable variability in the regimens preparatory for conditioning patients to be transplanted. In this systematic review, we identify the impact of reduced-intensity regimen (RIC) or non-myeloablative (NMAC) on HSCT in pediatric ALL patients in terms of overall survival (OS) and disease-free survival (DFS) as reported in the scientific literature. Information was searched on nine databases, gray literature and bibliography cited in the selected articles, describing the results of HSCT in ALL in children between January 01, 2007, and June 30, 2021, with different preparative regimens. The literature search yielded an overall of 3841 articles; two articles were duplicates and rejected. This first selection included 363 articles, and 95 were selected for a complete reading. Finally, 16 articles that met the inclusion and exclusion criteria were included, which analyzed 2136 patients with ALL. RIC, NMAC, or reduced-intensity myeloablative regimen (RTMAC) was administered to 520 patients, demonstrating OS and DFS like other cohorts undergoing MAC. This article concludes the use of RIC, NMAC, or RTMAC is a reasonable option for those patients with ALL who require a transplant and who suffer from other comorbidities or have previous transplants, offering survival rates comparable with myeloablative regimens that, in combination with new alternatives such as immunotherapy, may become the best alternative.
- Open Access
- 28 March 2023
- Published by Asociacion Colombiana de Gastroenterologia in Revista Colombiana de Gastroenterología
- Vol. 38 (1) , 12-18
Carga de enfermedad de cáncer gástrico desde 2010 hasta 2019 en Tunja, Boyacá, Colombia
Introducción: el cáncer gástrico (CG) es la primera causa de muerte por neoplasia en Colombia, con 6451 muertes durante el 2020 (1). Esta patología y sus manifestaciones crónicas plantean un desafío en la salud pública; el objetivo fue estimar la carga de enfermedad por CG en Tunja (Boyacá) durante los años 2010 a 2019. Metodología: se realizó un estudio ecológico exploratorio utilizando como unidad de medida los años de vida ajustados por discapacidad (AVAD). Se emplearon las bases de datos de mortalidad del Departamento Administrativo Nacional de Estadística (DANE), e información de la prevalencia desde los registros del Sistema Integrado de Información de la Protección Social (SISPRO). Las muertes y los casos de CG se agruparon y luego se ajustaron para controlar sesgos. Resultados: en el período 2010-2019, se perdieron 34,2 AVAD por cada 1000 personas secundario a CG en Tunja, Boyacá, Colombia, de los cuales 30,5 fueron debidos a años perdidos por muerte prematura y 3,72 por años vividos con discapacidad. Se encontró que los AVAD por muerte prematura superan a los AVAD por discapacidad. Conclusión: la carga de morbilidad por CG en el período 2010 a 2019 para la ciudad de Tunja fue similar a la carga de otros cánceres y fue debido a años de vida perdidos por muerte prematura, motivo por el cual se deben realizar esfuerzos de salud pública para aumentar la detección temprana.
- 28 March 2023
- Published by Asociacion Colombiana de Gastroenterologia in Revista Colombiana de Gastroenterología
- Vol. 38 (1) , 12-18
Open AccessCarga de enfermedad de cáncer gástrico desde 2010 hasta 2019 en Tunja, Boyacá, Colombia
Introducción: el cáncer gástrico (CG) es la primera causa de muerte por neoplasia en Colombia, con 6451 muertes durante el 2020 (1). Esta patología y sus manifestaciones crónicas plantean un desafío en la salud pública; el objetivo fue estimar la carga de enfermedad por CG en Tunja (Boyacá) durante los años 2010 a 2019. Metodología: se realizó un estudio ecológico exploratorio utilizando como unidad de medida los años de vida ajustados por discapacidad (AVAD). Se emplearon las bases de datos de mortalidad del Departamento Administrativo Nacional de Estadística (DANE), e información de la prevalencia desde los registros del Sistema Integrado de Información de la Protección Social (SISPRO). Las muertes y los casos de CG se agruparon y luego se ajustaron para controlar sesgos. Resultados: en el período 2010-2019, se perdieron 34,2 AVAD por cada 1000 personas secundario a CG en Tunja, Boyacá, Colombia, de los cuales 30,5 fueron debidos a años perdidos por muerte prematura y 3,72 por años vividos con discapacidad. Se encontró que los AVAD por muerte prematura superan a los AVAD por discapacidad. Conclusión: la carga de morbilidad por CG en el período 2010 a 2019 para la ciudad de Tunja fue similar a la carga de otros cánceres y fue debido a años de vida perdidos por muerte prematura, motivo por el cual se deben realizar esfuerzos de salud pública para aumentar la detección temprana.
- Open Access
- 1 June 2022
- Published by Instituto Nacional de Salud (Colombia) in Biomédica
- Vol. 42 (2) , 364-377
Eficacia de la tafenoquina en la profilaxis y tratamiento de la malaria por Plasmodium vivax, revisión sistemática y metaanálisis
Introducción. La tafenoquina fue aprobada en el 2018 por la Food and Drug Administration de Estados Unidos y, en el 2019, por la Therapeutic Goods Administration en Australia. Su administración en dosis única y su mecanismo de acción en las fases aguda y latente han sido objeto de estudio para cambiar el esquema de tratamiento de la malaria por Plasmodium vivax.Objetivo. Evaluar la evidencia científica disponible sobre la eficacia de la tafenoquina en la profilaxis y el tratamiento de la malaria por P. vivax, entre el 2009 y el 2019.Materiales y métodos. Se establecieron los descriptores MeSH y DeCS. Se utilizó la sintaxis ((Malaria Vivax) AND (tafenoquine) AND (prophylaxis)) OR [(Malaria Vivax) AND (tafenoquine) AND (relapse)] en las siguientes bases de datos: Pubmed, The Cochrane Central Register of Controlled Clinical Trials (CENTRAL), ISIS Web of Science, Lilacs y Scopus. Los resultados obtenidos se sometieron a análisis crítico (matriz CASPE). El análisis cuantitativo se realizó utilizando la diferencia de riesgos en análisis de supervivencia (Kaplan-Meier) en los tres artículos finales.Resultados. Se sometieron tres estudios a metaanálisis (Llanos-Cuentas, 2014; Llanos-Cuentas, 2019, y Lacerda, 2019) para evaluar la eficacia del tratamiento con tafenoquina en comparación con primaquina. Se obtuvo una diferencia de riesgo global de 0,04 (IC95% 0-0,08; p=0,07). La tafenoquina no mostró inferioridad en la eficacia del tratamiento frente al esquema de primaquina.Conclusión. La tafenoquina es una alternativa que mejora el cumplimiento del tratamiento, lo que podría acercar a Colombia a las metas de la Estrategia Técnica Mundial contra la Malaria, 2016-2030.
- 1 June 2022
- Published by Instituto Nacional de Salud (Colombia) in Biomédica
- Vol. 42 (2) , 364-377
Open AccessEficacia de la tafenoquina en la profilaxis y tratamiento de la malaria por Plasmodium vivax, revisión sistemática y metaanálisis
Introducción. La tafenoquina fue aprobada en el 2018 por la Food and Drug Administration de Estados Unidos y, en el 2019, por la Therapeutic Goods Administration en Australia. Su administración en dosis única y su mecanismo de acción en las fases aguda y latente han sido objeto de estudio para cambiar el esquema de tratamiento de la malaria por Plasmodium vivax.Objetivo. Evaluar la evidencia científica disponible sobre la eficacia de la tafenoquina en la profilaxis y el tratamiento de la malaria por P. vivax, entre el 2009 y el 2019.Materiales y métodos. Se establecieron los descriptores MeSH y DeCS. Se utilizó la sintaxis ((Malaria Vivax) AND (tafenoquine) AND (prophylaxis)) OR [(Malaria Vivax) AND (tafenoquine) AND (relapse)] en las siguientes bases de datos: Pubmed, The Cochrane Central Register of Controlled Clinical Trials (CENTRAL), ISIS Web of Science, Lilacs y Scopus. Los resultados obtenidos se sometieron a análisis crítico (matriz CASPE). El análisis cuantitativo se realizó utilizando la diferencia de riesgos en análisis de supervivencia (Kaplan-Meier) en los tres artículos finales.Resultados. Se sometieron tres estudios a metaanálisis (Llanos-Cuentas, 2014; Llanos-Cuentas, 2019, y Lacerda, 2019) para evaluar la eficacia del tratamiento con tafenoquina en comparación con primaquina. Se obtuvo una diferencia de riesgo global de 0,04 (IC95% 0-0,08; p=0,07). La tafenoquina no mostró inferioridad en la eficacia del tratamiento frente al esquema de primaquina.Conclusión. La tafenoquina es una alternativa que mejora el cumplimiento del tratamiento, lo que podría acercar a Colombia a las metas de la Estrategia Técnica Mundial contra la Malaria, 2016-2030.
- Open Access
- 20 January 2022
- Published by The Korean Academy of Family Medicine - M2PI in Korean Journal of Family Medicine
- Vol. 43 (1) , 27-36
Sedentarism, A Modifiable Risk Factor for Developing Chronic Kidney Disease in Healthy People
Background: Chronic kidney disease (CKD) is a consequence of the interaction of many pathophysiological processes, manifested by a decrease in the glomerular filtration rate (GFR) and abnormal kidney function. Sedentary behavior is associated with decreased kidney function, and regular physical activity could have the potential to reduce the risk of developing CKD, although this is not entirely clear. The objective of this study was to investigate the relationship between sedentary behavior and the development of CKD.Methods: A search was carried out in different databases and metasearchers from January 2015 to June 2020 for cross-sectional, case-control, and cohort studies, in which the association of a sedentary lifestyle or physical inactivity with the appearance of CKD was evaluated in healthy people. Eight articles were obtained, including six cross-sectional studies, one case-control, and one cohort study. The quality of evidence for the main outcomes was assessed using the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) model.Results: Most of the studies included in this systematic review agree that there is an association between a sedentary lifestyle and CKD; however, not all used the same definition of this disease, in the same way, the definitions of physical activity and sedentary behavior were different between these studies, as well as the methods of measuring sedentary behavior.Conclusion: CKD could be associated with sedentary behavior in previously healthy people. It was not possible to determine a measure of association with the available scientific evidence, as the study designs were heterogeneous. Modifiable risk factors should be considered in different population groups to reduce the risk of CKD.
- 20 January 2022
- Published by The Korean Academy of Family Medicine - M2PI in Korean Journal of Family Medicine
- Vol. 43 (1) , 27-36
Open AccessSedentarism, A Modifiable Risk Factor for Developing Chronic Kidney Disease in Healthy People
Background: Chronic kidney disease (CKD) is a consequence of the interaction of many pathophysiological processes, manifested by a decrease in the glomerular filtration rate (GFR) and abnormal kidney function. Sedentary behavior is associated with decreased kidney function, and regular physical activity could have the potential to reduce the risk of developing CKD, although this is not entirely clear. The objective of this study was to investigate the relationship between sedentary behavior and the development of CKD.Methods: A search was carried out in different databases and metasearchers from January 2015 to June 2020 for cross-sectional, case-control, and cohort studies, in which the association of a sedentary lifestyle or physical inactivity with the appearance of CKD was evaluated in healthy people. Eight articles were obtained, including six cross-sectional studies, one case-control, and one cohort study. The quality of evidence for the main outcomes was assessed using the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) model.Results: Most of the studies included in this systematic review agree that there is an association between a sedentary lifestyle and CKD; however, not all used the same definition of this disease, in the same way, the definitions of physical activity and sedentary behavior were different between these studies, as well as the methods of measuring sedentary behavior.Conclusion: CKD could be associated with sedentary behavior in previously healthy people. It was not possible to determine a measure of association with the available scientific evidence, as the study designs were heterogeneous. Modifiable risk factors should be considered in different population groups to reduce the risk of CKD.
- Open Access
- 8 April 2020
- Published by IntechOpen
Coinfection of Hepatitis B and C in HIV Patients: A Review of the State of the Art
Infection with the human immunodeficiency virus (HIV) modifies the course of infection by the virus of hepatitis B (HBV) by several mechanisms: the rate of chronicity, prolonging viremia by HBV, and increase in morbidity related to liver disease. The treatment for both infections should be done in a coordinated manner, to avoid the emergence of resistance in HIV, HBV or both, as well as major alterations in the hepatic enzymes. Monotherapies with lamivudine or emtricitabine select, rapidly, mutant strains of the HBV and HIV. Monotherapy with adefovir has moderate effects in coinfected patients as they already have mutations. If the treatment of HBV can defer until the combination antiretroviral therapy of HIV is necessary, these patients should receive a combination of tenofovir plus lamivudine (or emtricitabine), since this provides a powerful therapy against HBV and establishes a good central axis for antiretroviral therapy. In addition, it would prevent the selection of HBV variant resistance. The influence of HIV in the HCV infection. Increase in load HIV-driven viral hepatitis exacerbates hepatic lesions and influences transmission of the HCV. The risk of sexual transmission increases when HIV is present in the carrier. Coinfection modifies the evolution of fibrosis in patients with HIV, with higher speed in those who have low CD4 counts, so that the onset of cirrhosis occurs before, and the risk of liver decompensation is also more frequent. The consequence of this situation is an increase in liver-related morbidity and mortality.
- 8 April 2020
- Published by IntechOpen
Open AccessCoinfection of Hepatitis B and C in HIV Patients: A Review of the State of the Art
Infection with the human immunodeficiency virus (HIV) modifies the course of infection by the virus of hepatitis B (HBV) by several mechanisms: the rate of chronicity, prolonging viremia by HBV, and increase in morbidity related to liver disease. The treatment for both infections should be done in a coordinated manner, to avoid the emergence of resistance in HIV, HBV or both, as well as major alterations in the hepatic enzymes. Monotherapies with lamivudine or emtricitabine select, rapidly, mutant strains of the HBV and HIV. Monotherapy with adefovir has moderate effects in coinfected patients as they already have mutations. If the treatment of HBV can defer until the combination antiretroviral therapy of HIV is necessary, these patients should receive a combination of tenofovir plus lamivudine (or emtricitabine), since this provides a powerful therapy against HBV and establishes a good central axis for antiretroviral therapy. In addition, it would prevent the selection of HBV variant resistance. The influence of HIV in the HCV infection. Increase in load HIV-driven viral hepatitis exacerbates hepatic lesions and influences transmission of the HCV. The risk of sexual transmission increases when HIV is present in the carrier. Coinfection modifies the evolution of fibrosis in patients with HIV, with higher speed in those who have low CD4 counts, so that the onset of cirrhosis occurs before, and the risk of liver decompensation is also more frequent. The consequence of this situation is an increase in liver-related morbidity and mortality.